SlideShare a Scribd company logo
1 of 20
Download to read offline
100M people in the US suffer from a
problem for which we have a strong
solution. The patents are issued, we
are raising funds for FDA trial...
PAXEROL™ for NOCTURIA
07.21.2014
Misery associated with nocturia
Insomnia, fatigue, depression,
lower quality of life
US lost work time $60B/year
Incontinence care currently 25%
of the costs of nursing home care
Heart disease, stroke, brain
damage, hip fractures
NOCTURIA is the #1 urology
complaint of men and women 55-84
65%of people
ages 55-84
100Msufferers in US
(2.2B worldwide)
THIS IS A SIGNIFICANT UNMET MEDICAL NEED AS NO CURRENT
DRUG TREATS LOW NOCTURNAL BLADDER CAPACITY
2
Paxerol is a unique 8 hour extended release formulation
that provides increased nocturnal bladder capacity (NBC)
through the night. (+50-100%)
HOW IT WORKS: For 76% of people suffering from nocturia,
low NBC is a key issue. The cause is excess Prostaglandins
(PGE2) that irritate the bladder.
For sufferers of Nocturia and Over Active Bladder, a
combination of APAP & ibuprofen will inhibit PGE2
production to increase comfortable bladder capacity.
People are informally using the combination of already
approved drugs. It is proving effective for 80%. Our next step
is to prove efficacy in trials. Our use of these drugs for this
purpose and the addition of the timed release aspect are
protected by numerous broad patents.
3
INTRODUCING
APAP
ibuprofen
+ time release
Paxerol has three synergistic
mechanisms of action.
SCIENTIFIC ADVISORS
Frank Rauscher, III, Ph.D., Chief Scientist: Dep. Director, Wistar Inst.
Khurshid Iqbal, Ph.D., Pharma Chemist, J&J, Hoffmann-LaRoche
LEADING CLINICAL EXPERTS
Tony DelConte, MD, led Novartis Enablex FDA trials
Thomas Garvey III, MD, NIH, FDA, drug safety expert
LICENSING AND LEGAL
Joy Barton, Ph.D., Novartis, Licensing Agent
Ed Allera, Buchanan Ingersoll, FDA Focused Lawyer
Ping Wang MD IP Medical Expert Andrews Kurth, (named top 1000 patent Lawyer)
4
World Class Team
David Dill, CEO, IBM, CFO of 7 firms, 35 years as manager
6 Patents issued in 2012-2014 (16+ year life)
• Method of use claims; broad spectrum combinations.
• Covers use with Over Active Bladder (OAB)
• Extended release critical: 2-3 hour half life standard
• Wide range dosing of APAP with antimuscarinics, diuretics, antidiuretics,
spasmolytics, and/or NSAIDs.
• PCT process for worldwide protection filed 12/2010
5
Intellectual Property
8,236,857 B2 – Extended-release formulation
8,236,856 B2 – Delayed release formulation
8,685,453 B2 – Low dose APAP and NSAIDs
8,445,015 B2 – Extended-release formulation
8,445,011 B2 – Delayed-release formulation
8,703,184 B2 – Delayed-release formulation
US PATENTS ISSUED:
6
Vesicare, Enablex, Myrbetriq
• Effects often take months
• Large % do not respond
• Severe side effects
• 43–83% stop in < 30 days
• 10-15% fewer bathroom trips
• Treats annoying problem
• Significant competition
OVERACTIVE BLADDER DRUGS
2M
patients
(0.1%)
$2B
SALES
• Effects in as little as 30 mins.
• 80% positive (anecdotal)
• No side effects
• 20% drop out (anecdotal)
• 33-100% fewer nightly trips
• Treats dangerous problem
• No current competition
$2-8B
SALES ?
Proving effective for
OAB, but focused
on treatment of
bladder problems
related to sleep
7
Actionable Market
$2-8B
SALES
2018
Paxerol is a new product that is effective in ways that current OAB
(over active bladder) products are not.
*source 2013 Report by Debra E. Irwin et al / Company estimates
NOT A
SIGNIFICANT
PROBLEM
1 x per night
1.2 Billion
423 Million
Unaffordable
600 Million
130 Million No efficacy
50 Million Medical Issues
$0.30 / dose/daily = $39B
annual sales potential (retail)
NOTE: Forecasting a new market is
highly speculative.
2.4 Billion sufferers	
  es'mated	
  by	
  2018	
  	
  
Almost all regulatory bodies outside US permit use of unlicensed drugs
(“Specials”). We have an agreement for such distribution of Paxerol.
Contract signed April 2014 (Q1 2015 launch) with Ethicor Pharma, Ltd. (UK). Plan
to launch Paxerol with support of key opinion leaders, education sessions, and
published articles. Partnered with UDG, UK’s largest prescription drug distributor.
Ethicor exits when big pharma enters markets.
Top end price target – $5/dose controlled by Ethicor
Gross profit estimate – 98%
Only ages 60+, EU, MENA, and SA, with no advertising
8
Ethicor Short-term Revenues
2015 2016 2017 2018 2019 TOTAL
$832 $6,611 $26,949 $50,538 $73,161 $151,091
$k Ethicor Projected Income
We have protocol feedback and indications of interest from key
global pharmaceutical leaders.
Licensee to complete trials, patents, and launch Paxerol. We are expecting an
upfront payment after Phase 2 trial (mid-2015), milestone payments, 15% royalty.
9
Big Pharma License
Safe Drug, low risk Huge unmet need.
Tight patent barrier through 2030
10
Strengths of This Investment
This is not a new chemical entity. Approval can be attained
with a simpler, relatively inexpensive trial: Avoids Phase 1 Trial
safety tests, and years of risk from unexpected side effects.
Strong Ethicor validation. International sales begin before trial
completion, mitigates risk. Mid-2015 worldwide big pharma license.
Strong ROI @ up to 94% net profit.
$3M to positive Cash flow 12-15 months
1
2
3
4
5
$787K raised so far primarily through pooled
due diligence of Keiretsu Forum.
11
Use of Funds
Primary use of funds will be in the management of the trial
process and preparations for Ethicor launch.
Ethicor GP Rev Share
Expenses
Mfg. Testing
Clinical Trials
Business Dev.
Patents/ Legal WW
G&A / other
TOTAL Expenses
Net Income
2014 Q1 Q2 Q3
$42 $125 $221
$500 – – –
$612 $425 – –
$108 $29 $33 $38
$396 $130 $130 $90
$475 $55 $50 $50
$2,095 $639 $213 $178
($2,095) ($597) ($88) $43
Figures expressed as $k
2015
Profits in Q3 2015
12
Projections
Ethicor GP Rev Share
Big Pharma Milestones
Big Pharma Royalties
TOTAL Revenue
Expenses
Net Income
%
2014 2015 2016 2017 2018 2019 2020 2021
$1 $7 $27 $51 $73
– $13 $5 $5 $38
– – – – $15 $77 $307 $768
$0 $13 $12 $32 $103 $150 $307 $767
$2 $2 $1 $2 $6 $8 $16 $39
($2) $11 $11 $30 $97 $142 $291 $729
– 84% 92% 94% 95% 95% 95% 95%
Figures $Millions
Key Assumptions
1. FDA approval 2018 (no accelerated approval designation)
2. $0.30 retail ($0.15 wholesale) in 2018
3. 15% License fee (15-18% tiered structure would add $120M in 2021)
4. Licensing Agent 5% fee
5. A $5B big pharma drug by 2021 (no OAB or bedwetting solution)
Patents filed (issued 2012, 2013, & 2014)
FDA Confirms no Phase 1 safety tests required
EU“Special”Ethicor contract (launch Q1/2015)
Series A complete and trial contract signed
1st patient starts trial:
13 week crossover design; patients with 3+ voids/night
60 patient trial completed.
Sign big pharma license (Series A cash back)
FDA approval H1- Paxerol launch 6 weeks later
13
Milestones
7/2010
4/2012
4/2014
Q3/2014
Q2/2015
Q3/2015
2018
Q1/2015
• 22 patients informally tested Paxerol for a Johns Hopkins physician.
17 reported good results (fewer nightly bathroom trips). (77%)
• 18 patients have since tested Paxerol, with 15 reporting good results
(1-4 fewer nightly bathroom trips).
• Placebo effects are always possible, but much less likely when sleeping.
• 32 of 40 patients (80%) self-report success – without placebo controls.
• 3 articles report OAB suffers’urine averages 700% higher PGE2 levels -
Paxerol addresses PGE2 levels.
14
Anecdotal Evidence
Independent clinical studies consistently report that ~70% of nocturia patients
experience improvement when taking appropriate doses of certain NSAIDs
80% of patients with neurogenic bladder and 74% of patients with BPH
experience improvement in nocturia when taking appropriate doses of NSAIDs
(consistent with animal studies)
Johns Hopkins proves NSAIDs reduce bladder spasms
Ohio State preclinical model of bladder function showed acetaminophen equal
to NSAIDs in reducing inflammation, achieved through independent
mechanisms of action
Together acetaminophen and NSAIDs impact multiple independent molecular
pathways to relieve nocturia symptoms
15
Supporting Research
No matter how nice
your bathroom is, nobody wants
to visit in the middle of the night
17
OAB Market Segment
$2.1B
SALES
2011
*source 2013 Report by Debra E. Irwin et al / Company estimates
Astellas
VesiCare
3.8M
1.6 M Enablex
In the 12 months ending January 2012, more than 17.8 million
prescriptions were filled for drugs in the Over Active Bladder,
accounting for almost $2.1 billion in sales.
Oxybutynin
3.7M
Oxybutynin
ER 3.6M
Pfizer
Detrol LA
3.3 M
712 k Pfizer Toviaz
18
A Serious Problem
* Results from the Third National Health and
Nutrition Examination Study
12 year survival odds for
women ages 65-90 based on
nightly voiding episodes:
0 voids 68%
1 void 60%
2 voids 50%
3+ voids 22%
Association of Nocturia and
Mortality: Results From the
Third National Health and
Nutrition Examination Study
19
Clinical Trial Design
Inclusion Criteria
• Those who use bathroom 3+ times/night
• Those with elevated PGE2 levels
Exclusion Criteria
• Congestive heart failure, diabetes, etc.
• Those with major arthritis or muscle pains
13 week double blind crossover study
• Each patient tests all alternatives (to normalize variables)
• Paxerol, APAP, ibuprofen, placebo
• Show Paxerol’s superiority in reducing nocturia
• Delay time to first awakening
• Improve quality of life
20
Series A vs Series B
Both share 50% of returns until made whole for initial investment
Series A thereafter gets returns based on $1.10/share
Series B gets 50% until 15X invested $ back (1-4 years)
Inflated returns come from Founders, not Series A
Series B thereafter get returns based on $2.20/share

More Related Content

What's hot

Sr infographic automating ed followup - sept2014
Sr infographic   automating ed followup - sept2014Sr infographic   automating ed followup - sept2014
Sr infographic automating ed followup - sept2014Standard Register
 
The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...
The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...
The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...Healthcare Network marcus evans
 
Innovation in Clinical Trials
Innovation in Clinical Trials Innovation in Clinical Trials
Innovation in Clinical Trials Gary Monk
 
HCP Overview by Dr Bill Toth
HCP Overview by Dr Bill TothHCP Overview by Dr Bill Toth
HCP Overview by Dr Bill TothCreate Your Fate
 
MedicalResearch.com: Medical Research Exclusive Interviews June 6 2015
MedicalResearch.com:  Medical Research Exclusive Interviews June 6 2015MedicalResearch.com:  Medical Research Exclusive Interviews June 6 2015
MedicalResearch.com: Medical Research Exclusive Interviews June 6 2015Marie Benz MD FAAD
 
How is the Defined Contribution Marketplace Shaping the Industry?
How is the Defined Contribution Marketplace Shaping the Industry?How is the Defined Contribution Marketplace Shaping the Industry?
How is the Defined Contribution Marketplace Shaping the Industry?WEX Health Trends and Insights
 
EHR Meaningful Use for Medical Practices
EHR Meaningful Use for Medical PracticesEHR Meaningful Use for Medical Practices
EHR Meaningful Use for Medical PracticesMichael Patrick
 
Health Datapalooza 2013: Data Design Diabetes Demo Day Nuduro
Health Datapalooza 2013: Data Design Diabetes Demo Day NuduroHealth Datapalooza 2013: Data Design Diabetes Demo Day Nuduro
Health Datapalooza 2013: Data Design Diabetes Demo Day NuduroHealth Data Consortium
 
What's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelWhat's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
 
How Pharma Can Use Digital Health to Drive Value | A Medullan Webinar
How Pharma Can Use Digital Health to Drive Value | A Medullan WebinarHow Pharma Can Use Digital Health to Drive Value | A Medullan Webinar
How Pharma Can Use Digital Health to Drive Value | A Medullan WebinarMedullan
 
Third Place - iSeeInk
Third Place - iSeeInkThird Place - iSeeInk
Third Place - iSeeInkhealth2dev
 
The importance of GS1 standards in delivering efficiency and productivity pro...
The importance of GS1 standards in delivering efficiency and productivity pro...The importance of GS1 standards in delivering efficiency and productivity pro...
The importance of GS1 standards in delivering efficiency and productivity pro...GS1 UK
 
CommCare for WV BHAMC Child Survival Project
CommCare for WV BHAMC Child Survival ProjectCommCare for WV BHAMC Child Survival Project
CommCare for WV BHAMC Child Survival Projectjehill3
 
I reland feb 2014
I reland feb  2014 I reland feb  2014
I reland feb 2014 Paul Grundy
 
Quality And Performamce Measurement: The Massachusetts Experience
Quality And Performamce Measurement: The Massachusetts ExperienceQuality And Performamce Measurement: The Massachusetts Experience
Quality And Performamce Measurement: The Massachusetts ExperienceFrank Fortin
 
Five innovative technologies for health
Five innovative technologies for healthFive innovative technologies for health
Five innovative technologies for healthMpower Medical Inc
 

What's hot (20)

Sr infographic automating ed followup - sept2014
Sr infographic   automating ed followup - sept2014Sr infographic   automating ed followup - sept2014
Sr infographic automating ed followup - sept2014
 
The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...
The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...
The Value-Based Journey: An ACO Perspective-Steve Neorr, Triad HealthCare Net...
 
Kathy Payn Biomarkers White Paper
Kathy Payn Biomarkers White PaperKathy Payn Biomarkers White Paper
Kathy Payn Biomarkers White Paper
 
Innovation in Clinical Trials
Innovation in Clinical Trials Innovation in Clinical Trials
Innovation in Clinical Trials
 
HCP Overview by Dr Bill Toth
HCP Overview by Dr Bill TothHCP Overview by Dr Bill Toth
HCP Overview by Dr Bill Toth
 
MedicalResearch.com: Medical Research Exclusive Interviews June 6 2015
MedicalResearch.com:  Medical Research Exclusive Interviews June 6 2015MedicalResearch.com:  Medical Research Exclusive Interviews June 6 2015
MedicalResearch.com: Medical Research Exclusive Interviews June 6 2015
 
How is the Defined Contribution Marketplace Shaping the Industry?
How is the Defined Contribution Marketplace Shaping the Industry?How is the Defined Contribution Marketplace Shaping the Industry?
How is the Defined Contribution Marketplace Shaping the Industry?
 
EHR Meaningful Use for Medical Practices
EHR Meaningful Use for Medical PracticesEHR Meaningful Use for Medical Practices
EHR Meaningful Use for Medical Practices
 
Avinash kumar
Avinash kumarAvinash kumar
Avinash kumar
 
Health Datapalooza 2013: Data Design Diabetes Demo Day Nuduro
Health Datapalooza 2013: Data Design Diabetes Demo Day NuduroHealth Datapalooza 2013: Data Design Diabetes Demo Day Nuduro
Health Datapalooza 2013: Data Design Diabetes Demo Day Nuduro
 
What's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelWhat's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
 
How Pharma Can Use Digital Health to Drive Value | A Medullan Webinar
How Pharma Can Use Digital Health to Drive Value | A Medullan WebinarHow Pharma Can Use Digital Health to Drive Value | A Medullan Webinar
How Pharma Can Use Digital Health to Drive Value | A Medullan Webinar
 
Third Place - iSeeInk
Third Place - iSeeInkThird Place - iSeeInk
Third Place - iSeeInk
 
Mobile Health Technologies in Cardiovascular Disease
Mobile Health Technologies in Cardiovascular DiseaseMobile Health Technologies in Cardiovascular Disease
Mobile Health Technologies in Cardiovascular Disease
 
The importance of GS1 standards in delivering efficiency and productivity pro...
The importance of GS1 standards in delivering efficiency and productivity pro...The importance of GS1 standards in delivering efficiency and productivity pro...
The importance of GS1 standards in delivering efficiency and productivity pro...
 
Amarini_BMJ
Amarini_BMJAmarini_BMJ
Amarini_BMJ
 
CommCare for WV BHAMC Child Survival Project
CommCare for WV BHAMC Child Survival ProjectCommCare for WV BHAMC Child Survival Project
CommCare for WV BHAMC Child Survival Project
 
I reland feb 2014
I reland feb  2014 I reland feb  2014
I reland feb 2014
 
Quality And Performamce Measurement: The Massachusetts Experience
Quality And Performamce Measurement: The Massachusetts ExperienceQuality And Performamce Measurement: The Massachusetts Experience
Quality And Performamce Measurement: The Massachusetts Experience
 
Five innovative technologies for health
Five innovative technologies for healthFive innovative technologies for health
Five innovative technologies for health
 

Viewers also liked

Industrial Development Bank Of India
Industrial Development Bank Of IndiaIndustrial Development Bank Of India
Industrial Development Bank Of IndiaKrishna SN
 
NCV 2 New Venture Creation Hands-On Training - Module 3
NCV 2 New Venture Creation Hands-On Training - Module 3NCV 2 New Venture Creation Hands-On Training - Module 3
NCV 2 New Venture Creation Hands-On Training - Module 3Future Managers
 
Growth of vc in india
Growth of vc in indiaGrowth of vc in india
Growth of vc in indiaSandeep Singh
 
The Role of Multilateral Development Banks (MDBs) in the 2030 Agenda
The Role of Multilateral Development Banks (MDBs) in the 2030 AgendaThe Role of Multilateral Development Banks (MDBs) in the 2030 Agenda
The Role of Multilateral Development Banks (MDBs) in the 2030 AgendaMarc-Anton Pruefer
 
Strategic entrepreneurship Topic 8
Strategic entrepreneurship Topic 8Strategic entrepreneurship Topic 8
Strategic entrepreneurship Topic 8Anis Amira
 
Entrepreneurial strategies
Entrepreneurial strategiesEntrepreneurial strategies
Entrepreneurial strategiesFahim Akhtar
 
Mr. Mani Lal Chaudhary | sidbi schemes of financial assistance
Mr. Mani Lal Chaudhary |  sidbi schemes of financial assistanceMr. Mani Lal Chaudhary |  sidbi schemes of financial assistance
Mr. Mani Lal Chaudhary | sidbi schemes of financial assistancedhaval2929
 
Lecture 1 - New Venture Creation
Lecture 1 - New Venture CreationLecture 1 - New Venture Creation
Lecture 1 - New Venture Creationcommandeleven
 
Schemes offered by commercial banks
Schemes offered by commercial banksSchemes offered by commercial banks
Schemes offered by commercial banksPrachi Tiwari
 
Entrepreneurship & New Venture Creation-(3.1)-Module-1
Entrepreneurship & New Venture Creation-(3.1)-Module-1Entrepreneurship & New Venture Creation-(3.1)-Module-1
Entrepreneurship & New Venture Creation-(3.1)-Module-1VisualBee.com
 
Business Planning & Startup Strategies
Business Planning & Startup StrategiesBusiness Planning & Startup Strategies
Business Planning & Startup StrategiesArnab Ray
 

Viewers also liked (18)

Opus Life Stories -
Opus Life Stories - Opus Life Stories -
Opus Life Stories -
 
Investor Deck: A New Cause Marketing Model for Insurance
Investor Deck: A New Cause Marketing Model for InsuranceInvestor Deck: A New Cause Marketing Model for Insurance
Investor Deck: A New Cause Marketing Model for Insurance
 
Schemes of SIDBI
Schemes of SIDBISchemes of SIDBI
Schemes of SIDBI
 
Industrial Development Bank Of India
Industrial Development Bank Of IndiaIndustrial Development Bank Of India
Industrial Development Bank Of India
 
NCV 2 New Venture Creation Hands-On Training - Module 3
NCV 2 New Venture Creation Hands-On Training - Module 3NCV 2 New Venture Creation Hands-On Training - Module 3
NCV 2 New Venture Creation Hands-On Training - Module 3
 
Growth of vc in india
Growth of vc in indiaGrowth of vc in india
Growth of vc in india
 
The Role of Multilateral Development Banks (MDBs) in the 2030 Agenda
The Role of Multilateral Development Banks (MDBs) in the 2030 AgendaThe Role of Multilateral Development Banks (MDBs) in the 2030 Agenda
The Role of Multilateral Development Banks (MDBs) in the 2030 Agenda
 
Epm
Epm Epm
Epm
 
Strategic entrepreneurship Topic 8
Strategic entrepreneurship Topic 8Strategic entrepreneurship Topic 8
Strategic entrepreneurship Topic 8
 
Entrepreneurial strategies
Entrepreneurial strategiesEntrepreneurial strategies
Entrepreneurial strategies
 
Mr. Mani Lal Chaudhary | sidbi schemes of financial assistance
Mr. Mani Lal Chaudhary |  sidbi schemes of financial assistanceMr. Mani Lal Chaudhary |  sidbi schemes of financial assistance
Mr. Mani Lal Chaudhary | sidbi schemes of financial assistance
 
Lecture 1 - New Venture Creation
Lecture 1 - New Venture CreationLecture 1 - New Venture Creation
Lecture 1 - New Venture Creation
 
The evolution of toyota
The evolution of toyotaThe evolution of toyota
The evolution of toyota
 
Schemes offered by commercial banks
Schemes offered by commercial banksSchemes offered by commercial banks
Schemes offered by commercial banks
 
Entrepreneurship & New Venture Creation-(3.1)-Module-1
Entrepreneurship & New Venture Creation-(3.1)-Module-1Entrepreneurship & New Venture Creation-(3.1)-Module-1
Entrepreneurship & New Venture Creation-(3.1)-Module-1
 
Creating and starting the venture
Creating and starting the ventureCreating and starting the venture
Creating and starting the venture
 
New venture creation
New venture creationNew venture creation
New venture creation
 
Business Planning & Startup Strategies
Business Planning & Startup StrategiesBusiness Planning & Startup Strategies
Business Planning & Startup Strategies
 

Similar to New Venture Launch: Funding for trials for important new discovery

Virginia Llera - Cómo optimizar la investigación en Enfermedades Raras
Virginia Llera - Cómo optimizar la investigación en Enfermedades RarasVirginia Llera - Cómo optimizar la investigación en Enfermedades Raras
Virginia Llera - Cómo optimizar la investigación en Enfermedades RarasFundación Ramón Areces
 
IntelGenx Presentation Apr 2018
IntelGenx Presentation Apr 2018IntelGenx Presentation Apr 2018
IntelGenx Presentation Apr 2018ItelGenx
 
IGX Investor Presentation
IGX Investor PresentationIGX Investor Presentation
IGX Investor PresentationItelGenx
 
ARSTAT_Introduction
ARSTAT_IntroductionARSTAT_Introduction
ARSTAT_IntroductionArkady Rubin
 
Intelgenx presentation apr 2018
Intelgenx presentation apr 2018Intelgenx presentation apr 2018
Intelgenx presentation apr 2018ItelGenx
 
Company pres jpm final 01 09-2018-updated
Company pres jpm final 01 09-2018-updatedCompany pres jpm final 01 09-2018-updated
Company pres jpm final 01 09-2018-updatedItelGenx
 
Nanotechnology
NanotechnologyNanotechnology
NanotechnologyMewa Singh
 
Bellus corporate presentation feb 2015 (r)
Bellus corporate presentation feb 2015 (r)Bellus corporate presentation feb 2015 (r)
Bellus corporate presentation feb 2015 (r)BellusHealth
 
Bach Pharma GVT Informational Deck
Bach Pharma GVT Informational DeckBach Pharma GVT Informational Deck
Bach Pharma GVT Informational DeckJamieJamitkowski
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationRedChip Companies, Inc.
 
Corporate Presentation Fall 2014
Corporate Presentation Fall 2014Corporate Presentation Fall 2014
Corporate Presentation Fall 2014BellusHealth
 
WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?Healthegy
 

Similar to New Venture Launch: Funding for trials for important new discovery (20)

Launch of a new Pharmaceutical Product
Launch of a new Pharmaceutical ProductLaunch of a new Pharmaceutical Product
Launch of a new Pharmaceutical Product
 
Virginia Llera - Cómo optimizar la investigación en Enfermedades Raras
Virginia Llera - Cómo optimizar la investigación en Enfermedades RarasVirginia Llera - Cómo optimizar la investigación en Enfermedades Raras
Virginia Llera - Cómo optimizar la investigación en Enfermedades Raras
 
IntelGenx Presentation Apr 2018
IntelGenx Presentation Apr 2018IntelGenx Presentation Apr 2018
IntelGenx Presentation Apr 2018
 
Ophthotech
Ophthotech Ophthotech
Ophthotech
 
IGX Investor Presentation
IGX Investor PresentationIGX Investor Presentation
IGX Investor Presentation
 
ARSTAT_Introduction
ARSTAT_IntroductionARSTAT_Introduction
ARSTAT_Introduction
 
Intelgenx presentation apr 2018
Intelgenx presentation apr 2018Intelgenx presentation apr 2018
Intelgenx presentation apr 2018
 
ba401_genentech
ba401_genentechba401_genentech
ba401_genentech
 
BA401_Genentech
BA401_GenentechBA401_Genentech
BA401_Genentech
 
BA 401_Genenteach
BA 401_GenenteachBA 401_Genenteach
BA 401_Genenteach
 
ba401_genentech
ba401_genentechba401_genentech
ba401_genentech
 
Company pres jpm final 01 09-2018-updated
Company pres jpm final 01 09-2018-updatedCompany pres jpm final 01 09-2018-updated
Company pres jpm final 01 09-2018-updated
 
Nanotechnology
NanotechnologyNanotechnology
Nanotechnology
 
Akhu Therapeutics Pitch Deck
Akhu Therapeutics Pitch DeckAkhu Therapeutics Pitch Deck
Akhu Therapeutics Pitch Deck
 
Bellus corporate presentation feb 2015 (r)
Bellus corporate presentation feb 2015 (r)Bellus corporate presentation feb 2015 (r)
Bellus corporate presentation feb 2015 (r)
 
Bach Pharma GVT Informational Deck
Bach Pharma GVT Informational DeckBach Pharma GVT Informational Deck
Bach Pharma GVT Informational Deck
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. Presentation
 
Corporate Presentation Fall 2014
Corporate Presentation Fall 2014Corporate Presentation Fall 2014
Corporate Presentation Fall 2014
 
Drug Therapy Issues
Drug Therapy IssuesDrug Therapy Issues
Drug Therapy Issues
 
WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?
 

More from Wild Out West / Magnity Interactive (9)

Elemental Breath
Elemental BreathElemental Breath
Elemental Breath
 
OCLI
OCLIOCLI
OCLI
 
New Healthcare Venture -Helping people to create new habits
New Healthcare Venture -Helping people to create new habitsNew Healthcare Venture -Helping people to create new habits
New Healthcare Venture -Helping people to create new habits
 
WOWIntegratedMarketing0615
WOWIntegratedMarketing0615WOWIntegratedMarketing0615
WOWIntegratedMarketing0615
 
WOWIntegratedMarketingBOOK
WOWIntegratedMarketingBOOKWOWIntegratedMarketingBOOK
WOWIntegratedMarketingBOOK
 
WOW Integrated Marketing
WOW Integrated MarketingWOW Integrated Marketing
WOW Integrated Marketing
 
Success in Interactive Marketing
Success in Interactive MarketingSuccess in Interactive Marketing
Success in Interactive Marketing
 
Graphita Social Shirts
Graphita Social ShirtsGraphita Social Shirts
Graphita Social Shirts
 
Wow Introduction
Wow IntroductionWow Introduction
Wow Introduction
 

Recently uploaded

WheelTug PLC Pitch Deck | Investor Insights | April 2024
WheelTug PLC Pitch Deck | Investor Insights | April 2024WheelTug PLC Pitch Deck | Investor Insights | April 2024
WheelTug PLC Pitch Deck | Investor Insights | April 2024Hector Del Castillo, CPM, CPMM
 
Q1 Quarterly Update - April 16, 2024.pdf
Q1 Quarterly Update - April 16, 2024.pdfQ1 Quarterly Update - April 16, 2024.pdf
Q1 Quarterly Update - April 16, 2024.pdfProbe Gold
 
Corporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfCorporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfProbe Gold
 
Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024CollectiveMining1
 
Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...
Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...
Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...USDAReapgrants.com
 
Corporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfCorporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfProbe Gold
 
Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024CollectiveMining1
 
the 25 most beautiful words for a loving and lasting relationship.pdf
the 25 most beautiful words for a loving and lasting relationship.pdfthe 25 most beautiful words for a loving and lasting relationship.pdf
the 25 most beautiful words for a loving and lasting relationship.pdfFrancenel Paul
 
Q1 Probe Gold Quarterly Update- April 2024
Q1 Probe Gold Quarterly Update- April 2024Q1 Probe Gold Quarterly Update- April 2024
Q1 Probe Gold Quarterly Update- April 2024Probe Gold
 
slideshare_2404_presentation materials_en.pdf
slideshare_2404_presentation materials_en.pdfslideshare_2404_presentation materials_en.pdf
slideshare_2404_presentation materials_en.pdfsansanir
 

Recently uploaded (10)

WheelTug PLC Pitch Deck | Investor Insights | April 2024
WheelTug PLC Pitch Deck | Investor Insights | April 2024WheelTug PLC Pitch Deck | Investor Insights | April 2024
WheelTug PLC Pitch Deck | Investor Insights | April 2024
 
Q1 Quarterly Update - April 16, 2024.pdf
Q1 Quarterly Update - April 16, 2024.pdfQ1 Quarterly Update - April 16, 2024.pdf
Q1 Quarterly Update - April 16, 2024.pdf
 
Corporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfCorporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdf
 
Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024
 
Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...
Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...
Leveraging USDA Rural Development Grants for Community Growth and Sustainabil...
 
Corporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfCorporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdf
 
Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024Collective Mining | Corporate Presentation - April 2024
Collective Mining | Corporate Presentation - April 2024
 
the 25 most beautiful words for a loving and lasting relationship.pdf
the 25 most beautiful words for a loving and lasting relationship.pdfthe 25 most beautiful words for a loving and lasting relationship.pdf
the 25 most beautiful words for a loving and lasting relationship.pdf
 
Q1 Probe Gold Quarterly Update- April 2024
Q1 Probe Gold Quarterly Update- April 2024Q1 Probe Gold Quarterly Update- April 2024
Q1 Probe Gold Quarterly Update- April 2024
 
slideshare_2404_presentation materials_en.pdf
slideshare_2404_presentation materials_en.pdfslideshare_2404_presentation materials_en.pdf
slideshare_2404_presentation materials_en.pdf
 

New Venture Launch: Funding for trials for important new discovery

  • 1. 100M people in the US suffer from a problem for which we have a strong solution. The patents are issued, we are raising funds for FDA trial... PAXEROL™ for NOCTURIA 07.21.2014
  • 2. Misery associated with nocturia Insomnia, fatigue, depression, lower quality of life US lost work time $60B/year Incontinence care currently 25% of the costs of nursing home care Heart disease, stroke, brain damage, hip fractures NOCTURIA is the #1 urology complaint of men and women 55-84 65%of people ages 55-84 100Msufferers in US (2.2B worldwide) THIS IS A SIGNIFICANT UNMET MEDICAL NEED AS NO CURRENT DRUG TREATS LOW NOCTURNAL BLADDER CAPACITY 2
  • 3. Paxerol is a unique 8 hour extended release formulation that provides increased nocturnal bladder capacity (NBC) through the night. (+50-100%) HOW IT WORKS: For 76% of people suffering from nocturia, low NBC is a key issue. The cause is excess Prostaglandins (PGE2) that irritate the bladder. For sufferers of Nocturia and Over Active Bladder, a combination of APAP & ibuprofen will inhibit PGE2 production to increase comfortable bladder capacity. People are informally using the combination of already approved drugs. It is proving effective for 80%. Our next step is to prove efficacy in trials. Our use of these drugs for this purpose and the addition of the timed release aspect are protected by numerous broad patents. 3 INTRODUCING APAP ibuprofen + time release Paxerol has three synergistic mechanisms of action.
  • 4. SCIENTIFIC ADVISORS Frank Rauscher, III, Ph.D., Chief Scientist: Dep. Director, Wistar Inst. Khurshid Iqbal, Ph.D., Pharma Chemist, J&J, Hoffmann-LaRoche LEADING CLINICAL EXPERTS Tony DelConte, MD, led Novartis Enablex FDA trials Thomas Garvey III, MD, NIH, FDA, drug safety expert LICENSING AND LEGAL Joy Barton, Ph.D., Novartis, Licensing Agent Ed Allera, Buchanan Ingersoll, FDA Focused Lawyer Ping Wang MD IP Medical Expert Andrews Kurth, (named top 1000 patent Lawyer) 4 World Class Team David Dill, CEO, IBM, CFO of 7 firms, 35 years as manager
  • 5. 6 Patents issued in 2012-2014 (16+ year life) • Method of use claims; broad spectrum combinations. • Covers use with Over Active Bladder (OAB) • Extended release critical: 2-3 hour half life standard • Wide range dosing of APAP with antimuscarinics, diuretics, antidiuretics, spasmolytics, and/or NSAIDs. • PCT process for worldwide protection filed 12/2010 5 Intellectual Property 8,236,857 B2 – Extended-release formulation 8,236,856 B2 – Delayed release formulation 8,685,453 B2 – Low dose APAP and NSAIDs 8,445,015 B2 – Extended-release formulation 8,445,011 B2 – Delayed-release formulation 8,703,184 B2 – Delayed-release formulation US PATENTS ISSUED:
  • 6. 6 Vesicare, Enablex, Myrbetriq • Effects often take months • Large % do not respond • Severe side effects • 43–83% stop in < 30 days • 10-15% fewer bathroom trips • Treats annoying problem • Significant competition OVERACTIVE BLADDER DRUGS 2M patients (0.1%) $2B SALES • Effects in as little as 30 mins. • 80% positive (anecdotal) • No side effects • 20% drop out (anecdotal) • 33-100% fewer nightly trips • Treats dangerous problem • No current competition $2-8B SALES ? Proving effective for OAB, but focused on treatment of bladder problems related to sleep
  • 7. 7 Actionable Market $2-8B SALES 2018 Paxerol is a new product that is effective in ways that current OAB (over active bladder) products are not. *source 2013 Report by Debra E. Irwin et al / Company estimates NOT A SIGNIFICANT PROBLEM 1 x per night 1.2 Billion 423 Million Unaffordable 600 Million 130 Million No efficacy 50 Million Medical Issues $0.30 / dose/daily = $39B annual sales potential (retail) NOTE: Forecasting a new market is highly speculative. 2.4 Billion sufferers  es'mated  by  2018    
  • 8. Almost all regulatory bodies outside US permit use of unlicensed drugs (“Specials”). We have an agreement for such distribution of Paxerol. Contract signed April 2014 (Q1 2015 launch) with Ethicor Pharma, Ltd. (UK). Plan to launch Paxerol with support of key opinion leaders, education sessions, and published articles. Partnered with UDG, UK’s largest prescription drug distributor. Ethicor exits when big pharma enters markets. Top end price target – $5/dose controlled by Ethicor Gross profit estimate – 98% Only ages 60+, EU, MENA, and SA, with no advertising 8 Ethicor Short-term Revenues 2015 2016 2017 2018 2019 TOTAL $832 $6,611 $26,949 $50,538 $73,161 $151,091 $k Ethicor Projected Income
  • 9. We have protocol feedback and indications of interest from key global pharmaceutical leaders. Licensee to complete trials, patents, and launch Paxerol. We are expecting an upfront payment after Phase 2 trial (mid-2015), milestone payments, 15% royalty. 9 Big Pharma License
  • 10. Safe Drug, low risk Huge unmet need. Tight patent barrier through 2030 10 Strengths of This Investment This is not a new chemical entity. Approval can be attained with a simpler, relatively inexpensive trial: Avoids Phase 1 Trial safety tests, and years of risk from unexpected side effects. Strong Ethicor validation. International sales begin before trial completion, mitigates risk. Mid-2015 worldwide big pharma license. Strong ROI @ up to 94% net profit. $3M to positive Cash flow 12-15 months 1 2 3 4 5 $787K raised so far primarily through pooled due diligence of Keiretsu Forum.
  • 11. 11 Use of Funds Primary use of funds will be in the management of the trial process and preparations for Ethicor launch. Ethicor GP Rev Share Expenses Mfg. Testing Clinical Trials Business Dev. Patents/ Legal WW G&A / other TOTAL Expenses Net Income 2014 Q1 Q2 Q3 $42 $125 $221 $500 – – – $612 $425 – – $108 $29 $33 $38 $396 $130 $130 $90 $475 $55 $50 $50 $2,095 $639 $213 $178 ($2,095) ($597) ($88) $43 Figures expressed as $k 2015 Profits in Q3 2015
  • 12. 12 Projections Ethicor GP Rev Share Big Pharma Milestones Big Pharma Royalties TOTAL Revenue Expenses Net Income % 2014 2015 2016 2017 2018 2019 2020 2021 $1 $7 $27 $51 $73 – $13 $5 $5 $38 – – – – $15 $77 $307 $768 $0 $13 $12 $32 $103 $150 $307 $767 $2 $2 $1 $2 $6 $8 $16 $39 ($2) $11 $11 $30 $97 $142 $291 $729 – 84% 92% 94% 95% 95% 95% 95% Figures $Millions Key Assumptions 1. FDA approval 2018 (no accelerated approval designation) 2. $0.30 retail ($0.15 wholesale) in 2018 3. 15% License fee (15-18% tiered structure would add $120M in 2021) 4. Licensing Agent 5% fee 5. A $5B big pharma drug by 2021 (no OAB or bedwetting solution)
  • 13. Patents filed (issued 2012, 2013, & 2014) FDA Confirms no Phase 1 safety tests required EU“Special”Ethicor contract (launch Q1/2015) Series A complete and trial contract signed 1st patient starts trial: 13 week crossover design; patients with 3+ voids/night 60 patient trial completed. Sign big pharma license (Series A cash back) FDA approval H1- Paxerol launch 6 weeks later 13 Milestones 7/2010 4/2012 4/2014 Q3/2014 Q2/2015 Q3/2015 2018 Q1/2015
  • 14. • 22 patients informally tested Paxerol for a Johns Hopkins physician. 17 reported good results (fewer nightly bathroom trips). (77%) • 18 patients have since tested Paxerol, with 15 reporting good results (1-4 fewer nightly bathroom trips). • Placebo effects are always possible, but much less likely when sleeping. • 32 of 40 patients (80%) self-report success – without placebo controls. • 3 articles report OAB suffers’urine averages 700% higher PGE2 levels - Paxerol addresses PGE2 levels. 14 Anecdotal Evidence
  • 15. Independent clinical studies consistently report that ~70% of nocturia patients experience improvement when taking appropriate doses of certain NSAIDs 80% of patients with neurogenic bladder and 74% of patients with BPH experience improvement in nocturia when taking appropriate doses of NSAIDs (consistent with animal studies) Johns Hopkins proves NSAIDs reduce bladder spasms Ohio State preclinical model of bladder function showed acetaminophen equal to NSAIDs in reducing inflammation, achieved through independent mechanisms of action Together acetaminophen and NSAIDs impact multiple independent molecular pathways to relieve nocturia symptoms 15 Supporting Research
  • 16. No matter how nice your bathroom is, nobody wants to visit in the middle of the night
  • 17. 17 OAB Market Segment $2.1B SALES 2011 *source 2013 Report by Debra E. Irwin et al / Company estimates Astellas VesiCare 3.8M 1.6 M Enablex In the 12 months ending January 2012, more than 17.8 million prescriptions were filled for drugs in the Over Active Bladder, accounting for almost $2.1 billion in sales. Oxybutynin 3.7M Oxybutynin ER 3.6M Pfizer Detrol LA 3.3 M 712 k Pfizer Toviaz
  • 18. 18 A Serious Problem * Results from the Third National Health and Nutrition Examination Study 12 year survival odds for women ages 65-90 based on nightly voiding episodes: 0 voids 68% 1 void 60% 2 voids 50% 3+ voids 22% Association of Nocturia and Mortality: Results From the Third National Health and Nutrition Examination Study
  • 19. 19 Clinical Trial Design Inclusion Criteria • Those who use bathroom 3+ times/night • Those with elevated PGE2 levels Exclusion Criteria • Congestive heart failure, diabetes, etc. • Those with major arthritis or muscle pains 13 week double blind crossover study • Each patient tests all alternatives (to normalize variables) • Paxerol, APAP, ibuprofen, placebo • Show Paxerol’s superiority in reducing nocturia • Delay time to first awakening • Improve quality of life
  • 20. 20 Series A vs Series B Both share 50% of returns until made whole for initial investment Series A thereafter gets returns based on $1.10/share Series B gets 50% until 15X invested $ back (1-4 years) Inflated returns come from Founders, not Series A Series B thereafter get returns based on $2.20/share